| Literature DB >> 35493405 |
Lisa N Mansfield1, Richard J Chung2, Susan G Silva1, Elizabeth I Merwin3, Rosa M Gonzalez-Guarda1.
Abstract
Introduction: Human papillomavirus (HPV) vaccination can significantly reduce HPV-associated cancers. In the US, two doses are recommended for vaccine completion for younger adolescents. However, series completion rates remain below the nation's goal of 80% coverage. Multi-faceted factors may influence adolescent series completion. The purpose of this study was to identify individual-level, relationship-level, and community-level factors of timely series completion among adolescents, ages 11-14, initiating the HPV vaccine series in 2017.Entities:
Keywords: Adolescents; Cancer prevention; Human papillomavirus; Immunizations; Social determinants of health
Year: 2022 PMID: 35493405 PMCID: PMC9038569 DOI: 10.1016/j.ssmph.2022.101082
Source DB: PubMed Journal: SSM Popul Health ISSN: 2352-8273
Fig. 1Center for Disease Control and Prevention (CDC) Social-Ecological Model from “The Social-Ecological Model: A Framework for Prevention,” by National Center for Injury Prevention and Control, Division of Violence Prevention, 2022, (https://www.cdc.gov/violenceprevention/publichealthissue/social-ecologicalmodel.html). Reference to this framework does not constitute its endorsement or recommendation by the U.S. Government, Department of Health and Human Services, or Centers for Disease Control and Prevention. The material is otherwise available on the agency website for no charge.
Sample characteristics for quantitative sample.
| Characteristics | n (%) |
|---|---|
| HPV Vaccine Completion Status (N = 803) | |
| Overall Series Completion | 490 (61.0%) |
| Timely Series Completion | 380 (47.3%) |
| Required Dose for Completion (N = 803) | |
| Two Doses | 792 (98.6%) |
| Three Doses | 11 (1.4%) |
| Type of Visit at First Dose (N = 785) | |
| Well-Child Visit | 734 (93.5%) |
| Non-Well-Child Visit | 51 (6.5%) |
| Age at First Dose (N = 803) | |
| 11 | 331 (41.2%) |
| 12 | 261 (32.5%) |
| 13 | 127 (15.8%) |
| 14 | 84 (10.5%) |
| Sex (N = 803) | |
| Female | 399 (49.7%) |
| Male | 404 (50.3%) |
| Race/Ethnicity (N = 749) | |
| Hispanic | 109 (14.6%) |
| Non-Hispanic White | 246 (32.8%) |
| Non-Hispanic Black | 307 (41.0%) |
| Non-Hispanic Asian | 47 (6.3%) |
| Non-Hispanic Multiracial | 22 (2.9%) |
| Non-Hispanic Other | 18 (2.4%) |
| Insurance at First Dose (N = 803) | |
| No insurance | 4 (0.50%) |
| Private | 399 (49.7%) |
| Public | 400 (49.8%) |
| Area Deprivation Index Value at First Dose* (N = 775) | |
| 1–2 | 329 (42.5%) |
| 3–4 | 187 (24.1%) |
| 5–6 | 103 (13.2%) |
| 7–8 | 71 (9.2%) |
| 9–10 | 85 (11.0%) |
| Distance to Clinic at First Dose (N = 782) | |
| 0–15 miles | 536 (68.5%) |
| 16–30 miles | 216 (27.6%) |
| 31–45 miles | 30 (3.9%) |
Note. *Index value reported at the state-level ranging from 1 to 10.
Low values = low-deprivation neighborhoods; high values = high-deprivation neighborhoods.
Sample characteristics of qualitative sample.
| Characteristics | |||
|---|---|---|---|
| Adolescents (N = 16) | n | Caregivers (N = 16) | n |
| Age | Age | ||
| 11 | 1 | Less than 30 | 2 |
| 12 | 5 | 31–40 | 5 |
| 13 | 8 | 41–50 | 5 |
| 14 | 2 | 51–60 | 3 |
| 61–70 | 1 | ||
| Level of Education | Level of Education | ||
| Fifth grade | 1 | Less than high school | 1 |
| Sixth grade | 3 | Some high school, no diploma | 2 |
| Seventh grade | 8 | High school graduate | 2 |
| Eighth grade | 3 | Trade/technical school | 1 |
| Ninth grade | 1 | Some college, no degree | 4 |
| College graduate (Associates, Bachelors) | 2 | ||
| Graduate/Professional Degree | 4 | ||
| Race/ethnicity | Race/ethnicity | ||
| Non-Hispanic Black | 6 | Non-Hispanic Black | 5 |
| Non-Hispanic White | 3 | Non-Hispanic White | 5 |
| Non-Hispanic Other* | 2 | Non-Hispanic Other* | 1 |
| Hispanic | 5 | Hispanic | 5 |
| Sex | Relationship to Adolescent | ||
| Girls | 9 | Mothers | 14 |
| Boys | 7 | Grandmothers | 2 |
| Insurance Type | Annual Incomea | ||
| Private | 5 | Under $29,999 | 5 |
| Medicaid | 11 | $30,000 - $49,999 | 4 |
| Vaccine Completion Status | $50,000 - $74,999 | 4 | |
| Completer | 8 | $75,000 -$99,999 | 1 |
| Non-completer | 8 | $100,00 or more | 1 |
| Marital Status | |||
| Single | 7 | ||
| Married | 8 | ||
| Divorced | 1 | ||
Note. *Non-Hispanic Other represents participants self-identifying as multi-racial. aData collected from 15 of 16 caregivers.
Joint display of individual- and community-level determinants of timely series completion.
| Socioecological Domain | Explanatory Variables | aOR (95% CI) | Qualitative Subthemes & Quotes | Mixed-Methods Interpretation |
|---|---|---|---|---|
| Individual | Age at First Dose | |||
| 11 vs. 14 | ||||
| Race/Ethnicity | ||||
| Hispanic vs. NH-White | ||||
| NH-Black vs. NH-White | ||||
| NH-Black vs. NH-Other | ||||
| Sex | ||||
| Female vs. Male | 1.11 (0.81, 1.51) | |||
| Insurance | ||||
| Community | Distance to Clinic | |||
| 0–15 miles vs. 16–30 miles | 0.87 (0.61, 1.25) | |||
| 0–15 miles vs. 31–45 miles | 1.01 (0.45, 2.26) | |||
| 16–30 miles vs. 31–45 miles | 1.16 (0.50, 2.68) | |||
| State-Level Deprivationa | ||||
| 1–2 vs. 3–4 | 1.26 (0.83, 1.92) | |||
| 1–2 vs. 5–6 | 1.48 (0.86, 2.55) | |||
| 1–2 vs. 7–8 | 0.83 (0.44, 1.56) | |||
| 1–2 vs. 9–10 | 1.11 (0.60, 2.03) | |||
Note. Timely series completion reflects adolescents who completed recommended vaccine doses within 14-months. Boldface indicates statistical significance (*p < 0.05; **p < 0.01; ***p < 0.001). NH= Non-Hispanic. aOR = Adjusted odds ratios. CI = Confidence interval. a = Low values = low-deprivation neighborhoods; high values = high-deprivation neighborhoods.